Back to NAI500

Company Profile

Hemostemix, a World Economic Forum Technology Pioneer, trade marked the “Fountain of Youth”™ to summarize its proposition and focus to become the #1, Amazon-like-processor of the patient’s own stem cell therapies. Sourced from 250 ml of the patient’s blood, its patented platform generates multiple lineages ofstem cellsincluding angiogenic cell precursors (ACP) and neuronal cell precursors (NCP), treatments that regenerate circulation and nerve function. Critical limb ischemia and peripheral arterial disease, heart ischemia such as angina and ischemic cardiomyopathy, lung ischemia such as COPD and idiopathic pulmonary hypertension, have been treated safely and successfully. ACP’s current addressable markets, according to the Sage Group, exceed $800 Billion. 

  • Patented globally – 91 patents – including the scaling of its production processes 
  • 500 patients treated compassionately with significant clinical results published 
  • Finalizing its 17 center phase II clinical trial results and moving to a phase III 
  • The Company is set to commercialize in jurisdictions where permitted: China, Japan, S. Korea

Corporate Speaker

Thomas A. Smeenk hemostemix

Thomas A. Smeenk
Co-Founder, President & CEO

Mr. Smeenk is the Co-Founder, President & CEO of Hemostemix Inc. (HEM). He returned to the company in late 2019 and raised it $8 Million in 2020. A finance and business development executive with a proven track record of bringing new discoveries to market, Mr. Smeenk has been a public company executive since 1996. Prior to HEM, as President & CEO of Broadway Gold, Mr. Smeenk completed a $80 million earn-in agreement with Rio Tinto. Following that transaction, Broadway shareholders became shareholders of MindMed (1 for 8 MMED) and American Pacific Minerals (1 for 2 USGD). 

Company Website

Stock Info:

TSXV: HEM  OTC: HMTXF